Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp SPIROMAX and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment

Trial Profile

Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp SPIROMAX and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 03 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2016.
    • 02 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top